Busch C, et al. - In 24-month, retrospective, multinational, real-world study, investigators evaluated 155 eyes of 155 subjects to estimate the functional long-term outcome in subjects with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and also to recognize its clinical predictors. At 24 months, they noticed no altered mean best-corrected visual acuity (BCVA) in CRVO (−2.1±24.5 letters) and BRVO cases (1.3±27.0 letters). A worse baseline BCVA, visual acuity (VA) gain ≥5 letters at 2 months and no demand for adjunctive intravitreal therapy after the first DEX implant was correlated with a better final BCVA gain.